The reevaluation of innovative drug stocks is happening right now—did you get in on this wave?
Event Play | Dual Drivers of Policy and Orders Bring Long-Term Tailwinds for Overseas Innovative Drug Outsourcing (CXO)
Core Logic:By 2026, overseas CXOs will benefit from cyclical recovery, order reallocation driven by the Biosecure Act, capacity scarcity in emerging technology areas (ADC/peptides), and AI-driven reshaping of demand structures across segments;Non-Chinese CDMOs capable of absorbing relocated orders and possessing technological barriers, along with preclinical CROs exhibiting clear margin-recovery potential, are expected to benefit first.
【I. The Biosecure Act】
The U.S. Deputy Secretary of Defense has designated $WUXI APPTEC (02359.HK)$ as a "Chinese military company" under Section 1260H, affecting its commercial services, manufacturing, production, or export operations that are conducted directly or indirectly within the United States.
Wuxi Apptec stated that this designation is "clearly erroneous" and pledged to "immediately take action to challenge and rectify this mistaken designation."
📌 Core impact mechanism:
Inclusion on the 1260H list → automatic incorporation into the Biosecure Act (effective December 18, 2025) → federal agencies and recipients of federal loans or grants are prohibited from procuring equipment or services from "biotechnology companies of concern" (BCC).
Although Wuxi AppTec90%+derives its revenue from the private sector,it has in effect suppressed demand from U.S. contract biotech/pharmaceutical companies to collaborate with it.
📦 Foreign competitors benefiting from order migration:
• Polypeptide (PPGN.SW)
💡 Long-term rationale:
CurrentlyNeither Wuxi Bio nor Wuxi XDC has been included on the Section 1260H list, thus limiting sentiment-driven demand expectations for biologics or ADC manufacturing in the near term.
However, the U.S. Office of Management and Budget (OMB) will require approximately one year to release the initial list of companies and 180 days to issue guidance documents, while the Federal Acquisition Regulation (FAR) Council will also need about a year to revise procurement rules.
Therefore, implementation of the BIOSECURE Act is expected to take several years, meaning the strictest prohibitions would not take effect until roughly 2.5 to 3 years after the regulations become effective.
Meanwhile, existing contracts are expected to benefit from a five-year transition period, effectively safeguarding current arrangements and limiting short-term supply chain disruptions until around 2032.
Wuxi Apptec will continue to benefit in the near term from incremental peptide orders, which also caps near-term fundamental risks across the sector. Over the long run, this dynamic favors Western CXOs and should alleviate investor concerns about overcapacity or weak long-term demand. Valuation benchmarks for Western CDMOs are shifting from cyclical recovery toward structural market share gains.
[II. Logic Behind Realization of Biotech Financing Orders]
According to IQVIA monitoring, global biopharma financing reached USD 25 billion this quarter, nearly double the amount in the same period of 2025, indicating a gradual recovery in demand.
📣 Transmission chain:Biotech company fundraising → Pipeline advancement → Outsourcing demand, with a transmission lag of approximately 6–12 months.Apparent earnings recovery from H2 2026 to H1 2027 is data-supported, and preclinical CRO companies are poised to benefit.
✅ Positive signals:
• DSA business orders remain stable, with an order-to-shipment ratio of 1.04x and net order value consistently above USD 600 million
• Most clients have completed pipeline reorganization and reprioritization, leading to improved demand trends
• The company expresses relatively optimistic views on AI
⚠️ Drag on performance:
• The decline primarily stems from the impact of divested CDMO and Cell Solutions businesses under the BioSecure Act
• The Q1 revenue decline reflects a lagged effect of weak DSA orders in summer 2025
• Client spending levels have not yet recovered to historical norms
$Charles River (CRL.US)$70%Revenue comes from Discovery and Safety Assessment (DSA)—Highly regulated "wet lab" experiments that are inherently very difficult for AI to directly automate.
• AI is currently mainly used for early-stage target identification and molecular design
• Subsequent wet lab validation and toxicology assessments still need to be conducted by CRL
• AI reduces early-stage trial-and-error costs → more drug candidates advance to preclinical validation → expands the project funnel for CRL
Overall view: AI remains a positive catalyst for preclinical CROs; near-term earnings impact is limited, but the medium- to long-term logic for order growth is clear.
💉 [ADC CDMO]
📊 Market Size Forecast:
• Over1,100 for the full year
• The global ADC outsourcing market is expected to reach11 billion USD
• CAGR from 2024 to 2030 is projected at26.7%～31%
⚡ Supply-demand dynamics during the 2027 capacity release peak:
Global giants such as Lonza, Samsung Biologics, and Fujifilm have all coincidentally scheduled new capacity rollouts for 2027 to meet the anticipated wave of blockbuster ADC drug launches.
🏭 Progress of key players’ strategic moves:
• $FUJIFILM Holdings (4901.JP)$ : Expanding production in Texas, establishing an integrated end-to-end ADC platform from antibody to final conjugate, targeting U.S.-based localized orders
❓ Key risks:Will pharmaceutical companies choose to build their own ADC capacity rather than outsource it?This is a key variable that requires continuous monitoring.
Recommended ADC CDMO pick
[III. Divergence Among CROs in a Rising Rate Environment]
According to FOMC participant Kevin Warsh's remarks, the market has nearly priced in one rate hike in 2026 and expects another hike in 2027.
🔄 The impact of rate hikes on different types of CROs is clearly diverging:
CROs primarily serving large multinational pharma clients (e.g., $Fortrea Holdings (FTRE.US)$ ）： have relatively stable R&D spending, are less affected by financing conditions, and exhibit low sensitivity to rate hikes
→ tighter financing → client cash flow under pressure → higher order cancellation rates and declining new bookings
→ Highly sensitive to interest rate hikes, facing greater pressure
Detailed company comparison
[IV. Recent Guidance from Clinical CRO Companies]
• Total revenue for Q1:$4.15 billion, year-over-year+8.4%
• Net profit attributable to owners of parent:$274 million, year-over-year+10%
• R&D Solutions revenue:USD 2.397 billion, year-over-year+6.2%, organic growth3%
• Net new orders:USD 2.5 billion, double-digit year-over-year growth; order-to-shipment ratio1.04x
• Guidance: Maintained full-year revenue guidance, raised EBITDA toUSD 4.05–4.25 billionThe US Dollar
• Signals:Qualified pipeline of potential clients grew at a mid-single-digit rate year-over-year, while inquiry volume increased at a high-single-digit rate year-over-year ✅
• Q1 revenue:USD 636.5 million, year-over-year-2.3% net profit attributable to shareholders improved compared to the same period last year
• Book-to-bill ratio:1.15x (consistently above1.1x for three consecutive quarters)）
• Order backlog at quarter-end:USD 7.846 billion, year-over-year+1.6%
• Trend:CRO demand from biotech and large pharmaceutical clients continues to steadily improve; full-year guidance remains unchanged ✅
• Q1 revenue:USD 707 million, year-over-year+26.5%
• Net profit attributable to owners of parent:USD 124 million, year-over-year+8.1%
• Net new orders:6.2billion USD, year-over-year+23.7%, but significantly down quarter-over-quarter
• Book-to-bill ratio:0.88x(below 1), order burn rate23.3%, with growth primarily driven by fulfillment of existing orders
• Trend:High cancellation rates in chronic metabolic therapeutics; inquiry volume declined both year-over-year and quarter-over-quarter; share price plummeted after earnings release
• Risks:Sustainability of high growth is questionable, as client composition is highly sensitive to interest rate hikes
[Investment Advisory Information]
Freya Sun, FRM, CFA | SFC Central Reference Number: BWS708
[Risk Disclosure]
This material is provided by Futu Securities International (Hong Kong) Limited. The data and referenced information are for reference only. Past performance of any asset does not indicate future results and accuracy, completeness, or reliability cannot be guaranteed. The content herein does not constitute investment, legal, accounting, or tax advice, has not taken into account any individual’s investment objectives, financial situation, or specific needs, and does not amount to any recommendation, invitation, offer, or solicitation to buy or sell structured products. Investors should note that structured products are unsecured; in the event of insolvency or default by the issuer or guarantor, investors may recover only part or none of the amounts owed. Prices of structured products can rise or fall sharply, and investors may lose their entire investment. Investors rely solely on the creditworthiness of the issuer and guarantor when purchasing these products. Callable bull/bear contracts (CBBCs) are subject to mandatory call mechanisms and may be terminated early, in which case (i) investors in N-class CBBCs will receive no repayment, and (ii) the residual value of R-class CBBCs may become worthless. Investors should carefully review the listing documents (including any subsequent supplements and additional listing documents) for detailed information and risks associated with structured products and assess such risks independently. The products described on this page are structured investment products involving derivatives. They have not been authorized by the Securities and Futures Commission of Hong Kong (“SFC”) for public offering in Hong Kong, are not intended for the Hong Kong public, and are not protected by the Investor Compensation Fund. Investing in structured investment products is not equivalent to investing in their underlying reference assets. The structured investment products described herein may not be listed or may lack an active or liquid secondary market. Investors assume the credit and insolvency risks of the issuer, guarantor, and/or other identified counterparties, as applicable. Investors should also note that the issuer may terminate the investment early. Investment involves risk; investors should act prudently and fully understand that they may lose their entire investment. Before making any investment decision, investors should carefully read and understand the relevant offering documents and terms and conditions (including the risk disclosures therein) and should not rely solely on the content herein to decide whether to invest in structured investment products. Where necessary, appropriate professional advice should be sought.
[General Statement]
The author(s) of this report are licensed by the Securities and Futures Commission of Hong Kong. The analyst(s) and/or their associates do not hold any financial interest in the listed corporations covered in this research report. This report is prepared by Futu Securities International (Hong Kong) Limited (“Futu Securities”). By receiving and/or viewing this report (including any attachments), the recipient acknowledges and warrants that they are entitled to receive this report under the conditions set forth below and agrees to be bound by the restrictions contained herein. Any failure to comply with these restrictions may constitute a breach of applicable laws. Without prior written consent from Futu Securities, neither this report nor any information contained herein may be (i) reproduced, copied, or stored in any form, or (ii) distributed or transmitted directly or indirectly to any other person for any purpose. Futu Securities shall not be liable for any direct or indirect losses arising from the use of the materials contained in this report. The information in this report is derived from sources believed by Futu Securities to be accurate and reliable at the time of publication. However, this report is not intended to include all information necessary for investor decision-making and may be affected by delays, obstructions, or interceptions in transmission. Futu Securities makes no express or implied representation or warranty regarding the adequacy, accuracy, completeness, reliability, or fairness of any such information or opinions. Accordingly, Futu Securities and its affiliates (collectively, the “Futu Group”) shall not be liable for any losses of any kind (including, without limitation, direct, indirect, or consequential losses) arising from any actions taken by third parties in reliance on the content of this report.
The content, products, and services described in this report are intended solely for users in the Hong Kong Special Administrative Region and are provided for general circulation only. They do not constitute an offer or solicitation to buy or sell any investment product. This report does not take into account any individual’s specific investment objectives or financial circumstances. Individual investors should seek independent financial advisory or professional advice and refer to the relevant ETF offering documents and/or other latest published materials, including risk factors concerning the suitability of specific investment products. Data included in this report is sourced from publicly available information, which the analyst believes to be reliable. All investments involve risk, and investors may lose their entire invested capital. Past performance, estimates, forecasts, or simulated results do not necessarily indicate future performance of any investment. The ETFs referenced herein have not been and will not be authorized by the Securities and Futures Commission of Hong Kong under Section 104 of the Securities and Futures Ordinance. This report does not constitute, under Section 103 of the Securities and Futures Ordinance, an advertisement, invitation, or document inviting the Hong Kong public to acquire interests in or participate in a collective investment scheme.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment
1
2